Nivolumab Plus Ipilimumab Has Antitumor Activity in Metastatic RCC [Clinical Trials]
Nivolumab plus ipilimumab achieves durable responses and has manageable safety in metastatic RCC. (Source: Cancer Discovery)
Source: Cancer Discovery - August 31, 2017 Category: Cancer & Oncology Tags: Clinical Trials Source Type: research
Genomic Analysis Detects Recurrent Promoter Mutations in Breast Cancer [Breast Cancer]
Deep sequencing of 360 primary breast tumors identified 9 genes with recurrently mutated promoters. (Source: Cancer Discovery)
Source: Cancer Discovery - August 31, 2017 Category: Cancer & Oncology Tags: Breast Cancer Source Type: research
New SNPs from Testicular Cancer GWAS [News in Brief]
Two new genome-wide association studies identify 30 new risk variants for testicular cancer. One study suggests that genes involved in transcription regulation during development and microtubule assembly promote development of the disease. The second study implicates genes involved in mitochondrial metabolism, germ cell maturation, and DNA damage repair. (Source: Cancer Discovery)
Source: Cancer Discovery - August 31, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Savolitinib Heads for Phase III Trial in PRCC [News in Brief]
A phase II trial of savolitinib, a MET inhibitor, found that the drug induced partial responses in some patients with papillary renal cell carcinoma and was well tolerated, prompting drug makers Chi-Med and AstraZeneca to launch a phase III study. (Source: Cancer Discovery)
Source: Cancer Discovery - August 31, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
New Biomarker Identified for PDAC [News in Brief]
A new study suggests that the protein THBS2 could lead to early detection of pancreatic ductal adenocarcinoma. By testing for THBS2 and another marker, CA19-9, researchers identified blood samples from patients with the disease with 98% specificity and 87% sensitivity. (Source: Cancer Discovery)
Source: Cancer Discovery - August 31, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Epacadostat Shows Value in Two SCCHN Trials [News in Brief]
In the ECHO-202/KEYNOTE-037 and ECHO-204 trials reported at the 2017 Annual Meeting of the American Society of Clinical Oncology, patients with squamous cell carcinoma of the head and neck responded well to the combinations of epacadostat plus pembrolizumab and epacadostat plus nivolumab. An IDO1 inhibitor, epacadostat also demonstrated promising activity in combination with the PD-1 checkpoint inhibitors in other solid tumors, including melanoma, urothelial carcinoma, renal cell carcinoma, and non–small cell lung cancer. (Source: Cancer Discovery)
Source: Cancer Discovery - August 31, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Neratinib Approved for HER2+ Breast Cancer [News in Brief]
The FDA approved the tyrosine kinase inhibitor neratinib for extended adjuvant treatment of early-stage HER2-positive breast cancer. The decision adds another treatment option to help prevent recurrence, but its relatively small potential benefit must be weighed against the risk of serious side effects. (Source: Cancer Discovery)
Source: Cancer Discovery - August 31, 2017 Category: Cancer & Oncology Tags: News in Brief Source Type: research
Correction: Nods for Atezolizumab and Nivolumab from FDA [Correction]
(Source: Cancer Discovery)
Source: Cancer Discovery - August 1, 2017 Category: Cancer & Oncology Tags: Correction Source Type: research
Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade [Research Articles]
This study establishes Bap1 and Pbrm1 as lineage-specific drivers of ccRCC and histologic grade, implicates mTORC1 as a tumor grade rheostat, and suggests that ccRCCs arise from Bowman capsule cells.
Significance: Determinants of tumor grade and aggressiveness across cancer types are poorly understood. Using ccRCC as a model, we show that Bap1 and Pbrm1 loss drives tumor grade. Furthermore, we show that the conversion from low grade to high grade can be promoted by activation of mTORC1. Cancer Discov; 7(8); 900–17. ©2017 AACR.
See related commentary by Leung and Kim, p. 802.
This article is highlighted in the In...
Source: Cancer Discovery - August 1, 2017 Category: Cancer & Oncology Authors: Gu, Y.-F., Cohn, S., Christie, A., McKenzie, T., Wolff, N., Do, Q. N., Madhuranthakam, A. J., Pedrosa, I., Wang, T., Dey, A., Busslinger, M., Xie, X.-J., Hammer, R. E., McKay, R. M., Kapur, P., Brugarolas, J. Tags: Research Articles Source Type: research
PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability [Research Articles]
This article is highlighted in the In This Issue feature, p. 783 (Source: Cancer Discovery)
Source: Cancer Discovery - August 1, 2017 Category: Cancer & Oncology Authors: Gryder, B. E., Yohe, M. E., Chou, H.-C., Zhang, X., Marques, J., Wachtel, M., Schaefer, B., Sen, N., Song, Y., Gualtieri, A., Pomella, S., Rota, R., Cleveland, A., Wen, X., Sindiri, S., Wei, J. S., Barr, F. G., Das, S., Andresson, T., Guha, R., Lal-Nag, M Tags: Research Articles Source Type: research
Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers [Research Articles]
This article is highlighted in the In This Issue feature, p. 783 (Source: Cancer Discovery)
Source: Cancer Discovery - August 1, 2017 Category: Cancer & Oncology Authors: Glass, J. L., Hassane, D., Wouters, B. J., Kunimoto, H., Avellino, R., Garrett-Bakelman, F. E., Guryanova, O. A., Bowman, R., Redlich, S., Intlekofer, A. M., Meydan, C., Qin, T., Fall, M., Alonso, A., Guzman, M. L., Valk, P. J. M., Thompson, C. B., Levine Tags: Research Articles Source Type: research
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer [Research Articles]
This article is highlighted in the In This Issue feature, p. 783 (Source: Cancer Discovery)
Source: Cancer Discovery - August 1, 2017 Category: Cancer & Oncology Authors: Adeegbe, D. O., Liu, Y., Lizotte, P. H., Kamihara, Y., Aref, A. R., Almonte, C., Dries, R., Li, Y., Liu, S., Wang, X., Warner-Hatten, T., Castrillon, J., Yuan, G.-C., Poudel-Neupane, N., Zhang, H., Guerriero, J. L., Han, S., Awad, M. M., Barbie, D. A., Ri Tags: Research Articles Source Type: research
Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma [Research Articles]
This study identified two mechanistic subtypes of melanoma: (1) the best responders to clinical BRAF/MEK inhibitors (25%) and (2) nonresponders due to primary resistance mechanisms (9.9%). We identified robust biomarkers that can detect these subtypes in patient samples and predict clinical outcome. TBK1/IKBK inhibitors were selectively toxic to drug-resistant melanoma. Cancer Discov; 7(8); 832–51. ©2017 AACR.
See related commentary by Jenkins and Barbie, p. 799.
This article is highlighted in the In This Issue feature, p. 783 (Source: Cancer Discovery)
Source: Cancer Discovery - August 1, 2017 Category: Cancer & Oncology Authors: Eskiocak, B., McMillan, E. A., Mendiratta, S., Kollipara, R. K., Zhang, H., Humphries, C. G., Wang, C., Garcia-Rodriguez, J., Ding, M., Zaman, A., Rosales, T. I., Eskiocak, U., Smith, M. P., Sudderth, J., Komurov, K., Deberardinis, R. J., Wellbrock, C., D Tags: Research Articles Source Type: research
AACR Project GENIE: Powering Precision Medicine through an International Consortium [Research Articles]
This article is highlighted in the In This Issue feature, p. 783 (Source: Cancer Discovery)
Source: Cancer Discovery - August 1, 2017 Category: Cancer & Oncology Authors: The AACR Project GENIE Consortium Tags: Research Articles Source Type: research
Tumor Evolution as a Therapeutic Target [Review]
Recent technological advances in the field of molecular diagnostics (including blood-based tumor genotyping) allow the measurement of clonal evolution in patients with cancer, thus adding a new dimension to precision medicine: time. The translation of this new knowledge into clinical benefit implies rethinking therapeutic strategies. In essence, it means considering as a target not only individual oncogenes but also the evolving nature of human tumors. Here, we analyze the limitations of targeted therapies and propose approaches for treatment within an evolutionary framework.
Significance: Precision cancer medicine relies ...
Source: Cancer Discovery - August 1, 2017 Category: Cancer & Oncology Authors: Amirouchene-Angelozzi, N., Swanton, C., Bardelli, A. Tags: Review Source Type: research
